Dr. Reddy’s acquires Progynova and Cyclo-Progynova brands for $32 million, enhancing its presence in the hormone replacement ...

The acquisition has been valued at $32.15 million (approximately Rs 295 crore), the company disclosed under Regulation 30 of Sebi’s listing norms.

Dr Reddy's Laboratories has forayed into hormone replacement therapy segment by acquiring trademarks of specialty brands, ...

Dr. Reddy's Laboratories said that it has entered into a definitive agreement with Mercury Pharma Group (MPGL) to acquire its trademarks, Progynova and Cyclo Progynova and related assets for India.

Dr Reddy’s Laboratories has acquired the trademarks Progynova and CycloProgynova, along with related assets for India, from ...

Dr. Reddy’s Laboratories has acquired the trademarks of specialty brands Progynova and Cyclo-Progynova and related assets for India from the U.K.-headquartered Mercury Pharma Group.

Dr Reddy’s Laboratories Ltd is foraying into the hormone replacement therapy (HRT) segment in India with the acquisition of the trademarks and related assets for Progynova and Cyclo‑Progynova from ...

Nomura India said DRL's acquisitions over the past five years may contribute around one-quarter of the company’s revenues in FY26.

The Price section compares costs of the same generic drugs across brands and is purely for information purpose. Medindia neither buys nor sells drugs. Estradiol (Progynova (2 mg)) is a sex hormone, ...

Dr Reddy's Laboratories has acquired trademarks and assets of Progynova and Cyclo-Progynova from Mercury Pharma Group for USD 32.15 million. This acquisition marks the company's strategic entry into ...

Dr Reddy''s acquires Progynova & Cyclo-Progynova for USD 32.15 mn, entering the hormone replacement therapy market in India.

The Price section compares costs of the same generic drugs across brands and is purely for information purpose. Medindia neither buys nor sells drugs. Estradiol (Progynova (2 mg)) is a sex hormone, ...